Protamine-induced Acute Thrombosis in a Post-TAVR Patient: A Word of Caution
- PMID: 35779996
- DOI: 10.1016/j.carrev.2022.06.008
Protamine-induced Acute Thrombosis in a Post-TAVR Patient: A Word of Caution
Abstract
Major vascular complications after transcatheter aortic valve replacement (TAVR) are a pertinent issue and associated with increased morbidity and mortality. We herein describe a case of acute limb ischemia following the administration of protamine sulfate (PS) that was administered to mitigate a bleeding complication post-failure of a vascular access closure device. PS should be used cautiously for the prevention or management of bleeding-site complications following TAVR. The patient described in this case has consented to having his case described in this manuscript.
Keywords: Acute limb ischemia; Bleeding; Protamine sulfate; Thrombosis; Transcatheter aortic valve replacement.
Copyright © 2022. Published by Elsevier Inc.
Conflict of interest statement
Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Ron Waksman – Advisory Board: Abbott Vascular, Boston Scientific, Medtronic, Philips IGT, Pi-Cardia Ltd.; Consultant: Abbott Vascular, Biotronik, Boston Scientific, Cordis, Medtronic, Philips IGT, Pi-Cardia Ltd., Swiss Interventional Systems/SIS Medical AG, Transmural Systems Inc., Venous MedTech; Grant Support: AstraZeneca, Biotronik, Boston Scientific, Chiesi, Medtronic, Philips IGT; Speakers Bureau: AstraZeneca; Investor: MedAlliance, Transmural Systems Inc. All other authors – None.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
